Overall Survival In Evaluable For Efficacy Patients With Grade 2 Rash
Overall survival in evaluable-for-efficacy patients with grade ≥2 rash ...
Overall survival in evaluable-for-efficacy patients with grade ≥2 rash ...
Overall survival by grade of rash in patients treated with erlotinib in ...
The comparison of overall survival between patients with grade 2 and ...
The comparison of overall survival between patients with grade 2 and ...
Median Overall Survival in patients with rash was 7.33 months and in ...
Comparison of survival in patients with grade 2 and grade disease ...
Comparison of overall survival in patients with PNET with grade 1 ...
A, PFS for all evaluable patients with 95% CIs. B, overall survival for ...
Progression-free survival in evaluable-for-efficacy patients with grade ...
Advertisement Space (300x250)
Progression‑free and overall survival of patients with or without grade ...
Progression-free survival in evaluable-for-efficacy patients with grade ...
Progression‑free and overall survival of patients with or without grade ...
The Kaplan-Meier overall survival curve for all evaluable patients ...
Kaplan– Meier estimate of overall survival for all efficacy evaluable ...
Event‐free survival and overall survival in 30 evaluable patients ...
Event‐free survival and overall survival in 30 evaluable patients ...
Comparison of overall survival in patients with different groups. (A ...
(A) Two‐ year overall survival for all evaluable patients was 46.9% ...
Event‐free survival and overall survival in 30 evaluable patients ...
Advertisement Space (336x280)
(A) Two‐ year overall survival for all evaluable patients was 46.9% ...
Overall survival in groups with different efficacy of azacitidine ...
FIGURE Survival analysis of glioma patients with WHO grade e (n ...
Overall survival distribution of all the evaluable patients (n = 12 ...
Actuarial progression-free and overall survival curves for evaluable ...
Overall survival distribution of all the evaluable patients (n = 12 ...
The impact of grade on recurrence‐free and overall survival in ...
Progression-free survival and overall survival in 123 evaluable ...
Event-Free Survival for 44 evaluable patients and 18 deaths or episodes ...
Table 2 from Risk of High-Grade Skin Rash in Cancer Patients Treated ...
Advertisement Space (336x280)
Plot of overall actuarial survival of the 42 evaluable patients ...
Kaplan-Meier plots of overall survival (OS) in (A) all evaluable ...
FIGURE E Correlation of overall survival of patients with perihilar ...
Progression-free survival for all evaluable patients (A) and for ...
Comparison of overall survival between patients with assessment of ...
(A) Overall survival (OS) of patients in the NAÏVE cohort (59 patients ...